BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Treatment
379 results:

  • 1. Myotubularin-related-protein-7 inhibits mutant (G12V) k-ras by direct interaction.
    Weidner P; Saar D; Söhn M; Schroeder T; Yu Y; Zöllner FG; Ponelies N; Zhou X; Zwicky A; Rohrbacher FN; Pattabiraman VR; Tanriver M; Bauer A; Ahmed H; Ametamey SM; Riffel P; Seger R; Bode JW; Wade RC; Ebert MPA; Kragelund BB; Burgermeister E
    Cancer Lett; 2024 Apr; 588():216783. PubMed ID: 38462034
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming k-ras mutations and drug resistance in colorectal carcinoma.
    Song H; Li H; Shen X; Liu K; Feng H; Cui J; Wei W; Sun X; Fan Q; Bao W; Zhou H; Qian L; Nie H; Cheng X; Du Z
    Acta Biomater; 2024 Mar; 177():456-471. PubMed ID: 38331131
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
    Baranyi M; Molnár E; Hegedűs L; Gábriel Z; Petényi FG; Bordás F; Léner V; Ranđelović I; Cserepes M; Tóvári J; Hegedűs B; Tímár J
    Br J Cancer; 2024 Apr; 130(6):1059-1072. PubMed ID: 38278976
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Characteristic Mutational Damages in Gastric and colorectal Adenocarcinomas.
    Yermekova S; Orazgaliyeva M; Goncharova T; Rakhimbekova F; Kaidarova D; Shatkovskaya O
    Asian Pac J Cancer Prev; 2023 Nov; 24(11):3939-3947. PubMed ID: 38019254
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Small molecular inhibitors for KRAS-mutant cancers.
    Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
    Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Ferroptosis-Mediated Cell Death Induced by NCX4040, The Non-Steroidal Nitric Oxide Donor, in Human colorectal cancer Cells: Implications in Therapy.
    Sinha BK; Bortner CD; Jarmusch AK; Tokar EJ; Murphy C; Wu X; Winter H; Cannon RE
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371096
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Evaluation of
    Lastraioli E; Bettiol A; Iorio J; Limatola E; Checcacci D; Parisi E; Bianchi C; Arcangeli A; Iannopollo M; Di Costanzo F; Di Lieto M
    Cells; 2023 May; 12(11):. PubMed ID: 37296579
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study.
    Goktas Aydin S; Kavak EE; Topcu A; Bayramgil A; Akgul F; Kahraman S; Aykan MB; Altıntas YE; Helvaci K; Urun Y; Bilici A; Seker M; Sendur MAN; Olmez OF; Acikgoz O; Cicin I
    Biomol Biomed; 2023 Nov; 23(6):1089-1095. PubMed ID: 37289436
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. KRAS Pathways: A Potential Gateway for cancer Therapeutics and Diagnostics.
    Tripathi PK; Mittal KR; Jain N; Sharma N; Jain CK
    Recent Pat Anticancer Drug Discov; 2024; 19(3):268-279. PubMed ID: 37038676
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
    Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
    Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab.
    Li S; Yuan L; Yue M; Xu Y; Liu S; Wang F; Liu X; Wang F; Deng J; Sun Q; Liu X; Xue C; Lu T; Zhang W; Zhou J
    Cancer Imaging; 2023 Mar; 23(1):30. PubMed ID: 36964617
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Evaluating the Time Toxicity of cancer treatment in the CCTG CO.17 Trial.
    Gupta A; O'Callaghan CJ; Zhu L; Jonker DJ; Wong RPW; Colwell B; Moore MJ; Karapetis CS; Tebbutt NC; Shapiro JD; Tu D; Booth CM
    JCO Oncol Pract; 2023 Jun; 19(6):e859-e866. PubMed ID: 36881786
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer.
    Bhattacharya S
    Crit Rev Oncol Hematol; 2023 Mar; 183():103916. PubMed ID: 36717006
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Long-term benefits for lower socioeconomic groups by improving bowel screening participation in South Australia: A modelling study.
    Lal A; Gao L; Tan E; McCaffrey N; Roder D; Buckley E
    PLoS One; 2022; 17(12):e0279177. PubMed ID: 36542644
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.
    Garcia-Rendueles MER; Krishnamoorthy G; Saqcena M; Acuña-Ruiz A; Revilla G; de Stanchina E; Knauf JA; Lester R; Xu B; Ghossein RA; Fagin JA
    Mol Cancer; 2022 Dec; 21(1):213. PubMed ID: 36476495
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The potential mechanism of Neu5Gc inducing colorectal cancer based on network pharmacology and experimental validation.
    Zhang LC; Liu YN; La XQ; Yan SN; Chen Y; Liang JY; Li ZY
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Apr; 396(4):705-718. PubMed ID: 36456746
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. MSC-Derived exosomes suppress colorectal cancer cell proliferation and metastasis via miR-100/mTOR/miR-143 pathway.
    Jahangiri B; Khalaj-Kondori M; Asadollahi E; Purrafee Dizaj L; Sadeghizadeh M
    Int J Pharm; 2022 Nov; 627():122214. PubMed ID: 36152993
    [TBL] [Abstract] [Full Text] [Related]  

  • 18.
    Cruz-Nova P; Ocampo-García B; Carrión-Estrada DA; Briseño-Diaz P; Ferro-Flores G; Jiménez-Mancilla N; Correa-Basurto J; Bello M; Vega-Loyo L; Thompson-Bonilla MDR; Hernández-Rivas R; Vargas M
    Molecules; 2022 Aug; 27(17):. PubMed ID: 36080216
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Heteronemin and Tetrac Induce Anti-Proliferation by Blocking EGFR-Mediated Signaling in colorectal cancer Cells.
    Unson S; Chang TC; Yang YN; Wang SH; Huang CH; Crawford DR; Huang HM; Li ZL; Lin HY; Whang-Peng J; Wang K; Davis PJ; Li WS
    Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005485
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Management and outcome of colorectal cancer in a resource-limited setting: Ahmadu Bello university teaching hospital, Zaria, Nigeria.
    Theyra-Enias H; Tumba N; Popoola OB
    Niger J Clin Pract; 2022 Jun; 25(6):923-930. PubMed ID: 35708435
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 19.